Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>CLSA Raises SKB BIO-B's TP to HKD500.6, Reiterates Rating Outperform
Recommend 1 Positive 2 Negative 1 |
||||
|
||||
|
SKB BIO-B (06990.HK) saw a 31.3% YoY drop in its 1H25 turnover and recorded a net loss of RMB145 million, both better than expected, according to CLSA's research report. CLSA lifted its target price for SKB BIO-B from HKD328.4 to HKD500.6 and reiterated the Outperform rating. The report also mentioned the sales of SKB BIO-B's initial mid-term products amounted to RMB310 million, which was primarily driven by sac-TMT. It is expected that the label expansion for 2L NSCLC will push up their sales further in 2H25. AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
